| 191 |
B-lymphocyte stimulator: can we consider it a marker
for severity of hepatitis C virus-induced B-cell non-Hodgkin
lymphoma? |
2017 |
| 192 |
Bedside inflammatory mediators in pulmonary tuberculosis |
2017 |
| 193 |
CD30 expression versus serum soluble CD30 level as a prognostic markers in acute lymphoblastic leukemia |
2017 |
| 194 |
CD30 expression versus serum soluble CD30 level as a prognostic markers in acute lymphoblastic leukemia |
2017 |
| 195 |
CD30 expression versus serum soluble CD30 level as a prognostic markers in acute lymphoblastic leukemia |
2017 |
| 196 |
CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia |
2017 |
| 197 |
CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia |
2017 |
| 198 |
CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia |
2017 |
| 199 |
Characterization of the Pathogenicity of Novel Sequence Variants Identified in Type 1 VWD Subjects in the Zimmerman Program for the Molecular and Clinical Biology Study |
2017 |
| 200 |
Comparison of the Immunity Status in-Between Children with β-Thalassaemia
Major Receiving Different Treatment Modalities: A Single Egyptian District
Study |
2017 |
Do you have any questions? 
